αDC1 Vaccine + Pembrolizumab for Ovarian Cancer

This trial tests a new combination of treatments to boost the immune system's response against advanced ovarian cancer. The study adds a vaccine, called αDC1, and a drug called pembrolizumab (an immunotherapy) to a treatment plan that already includes chemotherapy. Participants will also take celecoxib, a common anti-inflammatory medication. This trial may suit women diagnosed with advanced-stage ovarian, tubal, or peritoneal cancer who have not yet received chemotherapy and can undergo surgery.

As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people, offering participants a chance to contribute to important advancements in cancer therapy.

Research has shown that the treatments in this trial, which include a mix of drugs and a vaccine, have shown promise in earlier studies. For example, a combination of rintatolimod, pembrolizumab, and cisplatin achieved a 50% success rate in treating ovarian cancer patients, with some remaining disease-free for over 70 months. However, some side effects were reported.

The αDC1 vaccine, added to the treatment plan, is considered safe based on previous research. It has been used with pembrolizumab in other trials without major safety concerns. Pembrolizumab, when combined with paclitaxel, is already FDA-approved for certain ovarian cancers and is known to extend patient survival, suggesting that this combination is generally well-tolerated.

Celecoxib, a COX2 inhibitor, enhances the effectiveness of paclitaxel and is commonly used for pain and inflammation, providing additional safety reassurance.

Researchers are excited about the combination of αDC1 Vaccine and Pembrolizumab for ovarian cancer because these treatments uniquely harness the power of the immune system to fight cancer. Unlike current standard treatments such as surgery and chemotherapy, which directly target cancer cells, Pembrolizumab is an immunotherapy that works by blocking a protein called PD-1, helping the immune system recognize and attack cancer cells more effectively. The αDC1 Vaccine is designed to boost the immune system further by training it to better identify ovarian cancer cells. Together, these therapies offer a promising new approach that could enhance the body's natural ability to combat cancer, potentially leading to more effective and sustainable outcomes.

Research has shown that the combination of treatments in this trial, including paclitaxel, cisplatin, rintatolimod, and pembrolizumab, holds promise for treating ovarian cancer. Participants may receive these treatments, with a previous study finding that 50% of patients responded and 79% experienced some clinical benefit—encouraging results for those with advanced ovarian cancer. Celecoxib, a drug that reduces inflammation, is also part of the treatment and has been shown to enhance paclitaxel's effectiveness by increasing cancer cell death. Additionally, pembrolizumab has improved survival rates when combined with chemotherapy for ovarian cancer. The αDC1 vaccine, included in one of the treatment arms, is under study for its potential to strengthen the immune system's fight against cancer cells. These findings suggest better outcomes for patients with advanced ovarian cancer.¹³⁴⁵⁶